DURHAM, NC, USA I2, 2025 I IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human ...

IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...

Immvention Therapeutix Inc. has entered into a collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease and other chronic conditions.

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Bagsværd, Denmark, 17 January 2025 - Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...

The bioinformatic analysis identified six transcription factors (NFKB2, RFX2, E2F5, ETV5, BACH1, and E2F7) as potential candidate genes for transcriptome regulation in SeMC-treated HD11 cells.

Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, ...